RxDoctor Payments Data

Nicole Jones, NP

Family · Cincinnati, OHNPI 1407001050

Payments from drug & device makers

$3,002in general payments, 2019–2025

Across 30 payments — averaging $100.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$629
  • Axsome Therapeutics, Inc.$432
  • Gilead$246
  • Biohaven Pharmaceutical Holding Company Ltd.$234
  • Evoke Pharma, Inc.$229
  • Novo Nordisk$195
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$3,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,002 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$42,363
Medicare patients
258
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$61,309
OzempicSemaglutide22$40,843
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$37,746
JardianceEmpagliflozin30$33,947
Nurtec OdtRimegepant Sulfate25$27,510
FarxigaDapagliflozin Propanediol18$18,649
TrulicityDulaglutide14$18,191
MounjaroTirzepatide11$10,489
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,109
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$8,595
SavellaMilnacipran Hcl12$6,032
Advair HfaFluticasone Propion/Salmeterol12$4,735
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,120
Atorvastatin Calcium339$2,750
Albuterol Sulfate HfaAlbuterol Sulfate91$2,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$195$40,84322 claims
AstraZenecaFarxiga, Breztri Aerosphere$629$28,75834 claims
Lilly USA, LLCTrulicity, Mounjaro$121$28,68025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →